ABBV stock falls 3% in a month amid takeover rumor denials, but Skyrizi and Rinvoq momentum and a deep pipeline support ...

AbbVie Inc. (NYSE:ABBV) is one of the best stocks for the next decade. On December 12, Morgan Stanley raised the firm’s price target on AbbVie to $269 from $261 with an Overweight rating on the shares ...

AbbVie has delivered strong YTD outperformance, with shares up nearly 30% and robust analyst optimism, but I maintain a 'Hold' rating. ABBV's growth is driven by Skyrizi and Rinvoq, offsetting Humira ...

AbbVie's major drugs, Skyrizi and Rinvoq, are generating lots of sales. Realty Income's diversified portfolio provides plenty of protection and monthly income. The JEPQ ETF employs a covered-call ...

AbbVie earns a buy rating, with strong 2025 EPS growth driven by Skyrizi and Rinvoq, despite pipeline concerns and a higher P/E. ABBV’s valuation remains attractive; a 14.4x FY 2027 multiple is ...

Wolfe is bullish on Merck & Company Inc (NYSE:MRK) while stepping back from AbbVie Inc (NYSE:ABBV). Analysts say the market is underestimating Merck’s ability to grow beyond Keytruda and has already ...

Psoriatic arthritis is an autoimmune condition that causes joint inflammation, skin symptoms, and pain. People searching for psoriatic arthritis prescriptions are often looking for detailed ...

AbbVie is a Dividend King that successfully navigated a challenging patent cliff. Coca-Cola is a household name that has survived and thrived for 139 years. Realty Income has increased its dividend ...